The Merkel Cell Carcinoma Market is expected to grow significantly in the 7MM, driven by the rising awareness among healthcare professionals contributing to earlier diagnosis, increasing chronic UV ...

Deborah S. Sarnoff, M.D., talks about the recent breakthrough treatments that are paving the way to treat patients with advanced basal cell carcinoma, squamous cell carcinoma and Merkel cell carcinoma ...

The following is a summary of “Improved survival at the population level for patients with advanced Merkel cell carcinoma ...

With the rising adoption of checkpoint inhibitors and combination therapies, BAVENCIO's market growth is driven by expanding indications and strategic partnerships. However, competition from ...

Interim Results from clinical study for cutaneous carcinomas presented at Late-Breaking Research SessionMarlborough, Massachusetts--(Newsfile ...

Older adults with HIV are at significantly higher risk for cutaneous malignancies when compared with younger patients with HIV.

ALTON Spring is just days away, the summer season will be here before we know it, temps will be getting warmer, and that means one thing more fun in the ...

The market for Bavencio (avelumab), the checkpoint inhibitor co-developed by Pfizer (NYSE: PFE) and Merck KGaA (MRK: DE), continues to grow as new indications drive demand. However, research from ...

Investment analysts at William Blair increased their Q2 2025 EPS estimates for shares of Incyte in a research note issued on Tuesday, March 18th. William Blair analyst M. Phipps now expects that the ...

Incyte (NASDAQ:INCY – Get Free Report) was downgraded by William Blair from an “outperform” rating to a “market perform” rating in a note issued to investors on Tuesday, Marketbeat.com reports.

TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome primary and acquired resistance to cancer immunotherapy, two ...